EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

JG26 attenuates ADAM17 metalloproteinase-mediated ACE2 receptor processing and SARS-CoV-2 infection in vitro

Valentina Gentili, Silvia Beltrami, Doretta Cuffaro, Giorgia Cianci, Gloria Maini, Roberta Rizzo, Marco Macchia, Armando Rossello, Daria Bortolotti, Elisa Nuti

Pharmacological Reports · 2025

DOI: 10.1007/s43440-024-00650-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacological Reports, 2025. Verfasst von Valentina Gentili und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, Via Luigi Borsari 46, Ferrara, 44121, Italy. Hauptthemen laut MEDLINE: ADAM17 Protein, Angiotensin-Converting Enzyme 2, SARS-CoV-2, Antiviral Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università di Pisa.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

ADAM17 is a metalloprotease implicated in the proteolysis of angiotensin-converting enzyme 2 (ACE2), known to play a critical role in the entry and spread of SARS-CoV-2. In this context, ADAM17 results as a potential novel target for controlling SARS-CoV-2 infection.

Methods

In this study, we investigated the impact on ACE2 surface expression and the antiviral efficacy against SARS-CoV-2 infection of the selective ADAM17 inhibitor JG26 and its dimeric (compound 1 ) and glycoconjugate (compound 2 ) derivatives using Calu-3 human lung cells.

Results

None of the compounds exhibited cytotoxic effects on Calu-3 cells up to a concentration of 25 µM. Treatment with JG26 resulted in partial inhibition of both ACE2 receptor shedding and SARS-CoV-2 infection, followed by compound 1 .

Conclusion

JG26, an ADAM17 inhibitor, demonstrated promising antiviral activity against SARS-CoV-2 infection, likely attributed to reduced sACE2 availability, thus limiting viral dissemination.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ADAM17 ProteinAngiotensin-Converting Enzyme 2SARS-CoV-2Antiviral AgentsCOVID-19 Drug TreatmentHumansCOVID-19Cell Line

Stichwörter der Autor:innen

ADAM17Antiviral activityArylsulfonamido-based hydroxamic acidSARS-CoV-2sACE2

Substanzen

ADAM17 ProteinAngiotensin-Converting Enzyme 2ADAM17 protein, humanACE2 protein, humanAntiviral Agents

Autor:innen und Institutionen

  • Department of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, Via Luigi Borsari 46, Ferrara, 44121, Italy.
  • Department of Pharmacy, University of Pisa, Via Bonanno 6, Pisa, 56126, Italy.
  • Clinical Research Center, LTTA, University of Ferrara, Ferrara, Italy.
  • Department of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, Via Luigi Borsari 46, Ferrara, 44121, Italy. brtdra@unife.it.
  • Department of Pharmacy, University of Pisa, Via Bonanno 6, Pisa, 56126, Italy. elisa.nuti@unipi.it.

Förderung

  • Università di Pisa

Zitieren

APA

Gentili, V., Beltrami, S., Cuffaro, D., Cianci, G., Maini, G., Rizzo, R., Macchia, M., Rossello, A., Bortolotti, D., & Nuti, E. (2025). JG26 attenuates ADAM17 metalloproteinase-mediated ACE2 receptor processing and SARS-CoV-2 infection in vitro. Pharmacological Reports. https://doi.org/10.1007/s43440-024-00650-0

Vancouver

Gentili V, Beltrami S, Cuffaro D, Cianci G, Maini G, Rizzo R, et al. JG26 attenuates ADAM17 metalloproteinase-mediated ACE2 receptor processing and SARS-CoV-2 infection in vitro. Pharmacological Reports. 2025. doi:10.1007/s43440-024-00650-0

BibTeX
@article{Gentili2025,
  author = {Gentili, Valentina and Beltrami, Silvia and Cuffaro, Doretta and Cianci, Giorgia and Maini, Gloria and Rizzo, Roberta and Macchia, Marco and Rossello, Armando and Bortolotti, Daria and Nuti, Elisa},
  title = {JG26 attenuates ADAM17 metalloproteinase-mediated ACE2 receptor processing and SARS-CoV-2 infection in vitro},
  journal = {Pharmacological Reports},
  year = {2025},
  doi = {10.1007/s43440-024-00650-0}
}
Kostenlos starten →